Molecular Targets Phase III CoBRE

描述(由申请人提供)：路易斯维尔大学生物医学研究卓越分子靶标中心(MT Cobre)和詹姆斯·格雷厄姆·布朗癌症中心在其第一阶段和第三阶段资助期间成功地支持了14名初级教员的早期职业生涯。目前的应用反映了分子靶标计划及其人员的成熟。分子靶标Cobre第三阶段应用的总体目标将是确保MT Cobre教职员工已经确定的新靶标和化合物被转化为关键的人类临床试验。有几个优势加强了该项目的成功，包括：1)项目领导的稳定性；2)成功地留住了所有14名教职员工；3)为该项目提供了总计超过3000万美元的机构支持；以及4)创建了路易斯维尔大学拥有的一家公司，致力于翻译MT Cobre调查人员的重要发现。MT Cobre教员在人体上测试他们的新化合物的能力将使这个项目有别于其他机构的类似项目。为此，MT Cobre支持了一个独特的翻译研究基础设施的发展，该基础设施已经能够表征30多个新的目标。第三阶段应用程序将密切支持四个 支持这一目标的集成核心设施：1)微阵列核心；2)分子建模核心；3)核磁共振/代谢核心；4)动物模型核心。此外，詹姆斯·格雷厄姆·布朗癌症中心还创建了补充性研究核心，将在计划的第三阶段向MT计划成员提供，包括生物统计核心、临床试验办公室、生物物理癌症核心、细胞分类和流式细胞术核心。MT Cobre政府将继续为14名教职员工的发展提供密集支持，其中许多人在癌症中心和大学担任领导职务。詹姆斯·格雷厄姆·布朗癌症中心和路易斯维尔大学强大的翻译研究基础设施将确保这一独特计划的成功和可持续性。

DESCRIPTION (provided by applicant): The Molecular Targets Center of Biomedical Research Excellence (MT COBRE) at the University of Louisville and the James Graham Brown Cancer Center has successful supported the early career of fourteen junior faculty members during its Phase I and il funding periods. The current application reflects the maturation of the Molecular Targets Program and its faculty. The overall goal of the Phase III application of the Molecular Targets COBRE will be to ensure that the novel targets and compounds which have been identified by MT COBRE faculty are translated to pivotal human clinical trials. Several strengths have enhanced the success of this program including: 1) Stability of program leadership; 2) Successful retention of all fourteen faculty members; 3) Institutional support for the program totaling over $30M; and 4) Creation of a University of Louisville-owned company dedicated to translating important discoveries of MT COBRE investigators. The ability of MT COBRE faculty to test their novel compounds in humans will distinguish this program from similar programs at other institutions.' To this end, the MT COBRE has supported the development of a unique translational research infrastructure which has enabled the characterization of more than 30 novel targets. The Phase III application will support four closely integrated core facilities which will support this goal; 1) Microarray Core; 2) Molecular Modeling Core; 3) NMR/Metabolomic Core and 4) Animal Model Core. Additionally, the James Graham Brown Cancer Center has created complementary research cores which will be available to MT Program members during the Phase III component of the program including the Biostatistics Core, Clinical Trials Office, Biophysical Cancer Core, Cell Sorting and Flow Cytometry Core. The MT COBRE administration will continue to provide intensive support for development of the fourteen faculty members, many of whom have assumed leadership roles within the Cancer Center and University. The robust translational research infrastructure at the James Graham Brown Cancer Center and University of Louisville will ensure the success and sustainability of this unique program.